Pricing
  1. JP-listed companies
  2. ADR120S, Inc.
  3. Financials
  4. Pretax margin (%)

ADR120S, Inc.【JP:3750】

Market cap
¥7.9B
P/E ratio
110.7x
Saitori Cell Research Institute develops regenerative cell therapies and medical devices while also investing in real estate projects through seven subsidiaries.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndPretax margin (%) YoY (%)
Mar 31, 2025-707.8+1118.07%
Mar 31, 2024-58.1+44.53%
Mar 31, 2023-40.2+28.43%
Mar 31, 2022-31.3-41.72%
Mar 31, 2021-53.7+241.83%
Mar 31, 2020-15.7-247.90%
Mar 31, 201910.6-56.50%
Mar 31, 201824.4-265.32%
Mar 31, 2017-14.8+60.29%
Mar 31, 2016-9.2-193.78%
Mar 31, 20159.8+15.76%
Mar 31, 20148.5-418.08%
Mar 31, 2013-2.7-0.40%
Mar 31, 2012-2.7

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)